Media statements

Roche confirms participation in FDA Oncologic Drug Advisory meeting on 20 May 2025

PDF

Roche’s Greenhouse Gas Reduction Targets Validated by the Science Based Targets initiative (SBTi)

PDF

WHO approves Roche’s mpox diagnostic test for emergency use, boosting global access

PDF

Roche submits science-based targets for net zero by 2045

PDF

Roche enters into a definitive agreement with Lonza, which will acquire the Genentech manufacturing facility in Vacaville, California, USA

PDF

Roche actively advances sector decarbonisation ahead of COP28

PDF

Roche launches a new addition to the cobas® connection modules, the CCM Vertical, helping to improve laboratory efficiency

PDF

FDA grants accelerated approval of Elevidys™, the first gene therapy to treat

PDF

Roche to divest legacy Genentech facility in Vacaville, California, as part of long-term strategy to evolve manufacturing capabilities

PDF

Adoption of the Resolution on Strengthening Diagnostics capacity at the 76th World Health Assembly

PDF

CHMP recommends Ronapreve for the treatment of hospitalised COVID-19 patients

PDF

Roche statement on FDA Oncologic Drug Advisory meeting on 9 March 2023

PDF

Roche provides update on Tecentriq US indication for previously untreated metastatic bladder cancer

PDF

Roche signs up to the Science Based Targets initiative and the Sustainable Markets Initiative to further deepen the commitment to climate actions

PDF

Roche and the World Health Organization partner to improve access to Actemra®/RoActemra® (tocilizumab) for COVID-19 in low- and middle-income countries

PDF

Additional studies confirm Roche SARS-CoV-2 Rapid Antigen Tests’ sensitivity against Omicron variant

PDF

Viruses mutate over time, and SARS-CoV-2 is no exception

PDF

How Roche tests and medicines continue to play a key role as pandemic evolves

PDF

Ronapreve does not retain neutralising activity against the Omicron variant

PDF

Roche statement on termination of partnership with Atea Pharmaceuticals to develop AT-527November 16, 2021

PDF

Roche statement on follow-up analysis of Ronapreve phase III prevention trial

PDF

WHO recommends the use of Ronapreve™ (casirivimab and imdevimab) in COVID-19 patients

PDF

Roche statement on global supply constraints of Actemra/RoActemra

PDF

World Health Organization issues new treatment recommendations for the clinical management of COVID-19

PDF

Roche statement on the preliminary phase III data from UK University of Oxford-led RECOVERY trial for casirivimab and imdevimab

PDF

Roche statement on FDA Oncologic Drug Advisory Meetings on 27–29 April 2021

PDF

Roche statement on the European Medicines Agency (EMA) commencement of review for Regeneron’s antibody cocktail (casirivimab and imdevimab)

PDF

Roche statement on casirivimab and imdevimab data in preventing COVID-19 infections within households

PDF

Roche statement on casirivimab and imdevimab data in hospitalised patients

PDF

Roche statement on new variants of SARS-CoV-2 found in the UK

PDF

Roche statement on FDA acceptance of casirivimab and imdevimab (REGNCOV2) EUA in the US

PDF

Changes recommended to ongoing REGN-COV2 study in hospitalized patients by Independent Data Monitoring Committee

PDF

Roche statement on REGN-COV2 data in non-hospitalised patients

PDF

Roche statement on REGN-COV2 US Emergency Use Authorization Request

PDF

Roche statement regarding UK diagnostics products supply issue

PDF

Roche statement on REGN-COV2 virology phase II data

PDF